Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 2

Y-90 SIRT for Unresectable HCC Larger Than 7cm

NCT06707233 · tracked via the Priya Life Science China tracker
Phase
Phase 2
Started
2024-12-01
Last updated
2025-01-28

Condition(s) studied

Hepatocellular Carcinoma Non-Resectable

Investigational drug(s) / intervention(s)

SIRT

SIRT: The patients will receive 1-2 sessions of SIRT.

Study summary

This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy. The primary endpoint of the study is objective reponse rate (ORR) as assessed by mRECIST. Secondary endpoints were: objective response rate (ORR) as assessed by RECIST 1.1, disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DOR), overall survival (OS), and safety (incidence and severity of adverse events).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Pathologically confirmed or clinically diagnosed HCC * Unresectable HCC as assessed by a team of surgeons * The largest tumor size \> 7 cm * Tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment * At least one measurable intrahepatic target lesion * Appropriate for SIRT treatment after evaluation (including SPECT/CT evaluation after arterial perfusion with 99Tc-MAA) * Child-Pugh score ≤ 7 * ECOG PS ≤ 1 * Adequate organ and hematologic function with platelet count ≥75×10\^9/L, leukocyte \>3.0×10\^9/L, Neutrophil count ≥1.5×10\^9/L, haemoglobin ≥85 g/L, ALT and AST≤5×ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds * life expectancy of at least 6 months Exclusion Criteria: * Macrovascular invasion or extrahepatic metastasis * Decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy * Organ (heart and kidneys) dysfunction * History of other malignancies * Uncontrollable infection * History of organ or cells transplantation * History of HIV * Pregnant or lactating patients

Primary outcome measure(s)

  • Objective response rate (ORR) per mRECIST — 3 years
    The proportion of patients with the best response of complete response (CR) or partial response (PR) according to mRECIST

Trial sites (2)

FacilityCityRegionStatus
The Second Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong Not Yet Recruiting
The Second Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06707233 on ClinicalTrials.gov ↗ ← All trials in China